The Q4 2026 HLP003 Phase 3 topline readout is the primary catalyst. The $50 million offering extends the cash runway but also dilutes existing holders. Monitor enrollment completion and any early efficacy signals from the APPROACH study. The widening loss and cash burn rate suggest the company will need additional capital before potential commercialization in 2028.
Price Chart
Executive Summary
Cybin Inc. (HELP) reported fiscal year 2026 financial results showing a net loss of $148.0 million, nearly double the prior year's $81.6 million loss, with cash-based operating expenses rising to $131.7 million from $71.8 million. The company highlighted 88% enrollment in its Phase 3 APPROACH study for HLP003 (on track for Q4 2026 topline data), closed a $50 million underwritten offering post-period, and noted positive Phase 2 data for HLP004 in GAD. Despite pipeline progress, the widening losses and cash burn rate raise concerns about capital efficiency ahead of pivotal readouts.
Key Facts
- Net loss for fiscal year 2026 was $148.0 million, up from $81.6 million in fiscal year 2025.
- Cash-based operating expenses (R&D, G&A) totaled $131.7 million for fiscal year 2026, up from $71.8 million.
- Cash flows used in operating activities were $133.3 million for fiscal year 2026, versus $72.3 million in the prior year.
- Cash totaled $157.3 million as of March 31, 2026; a $50 million underwritten offering closed on June 25, 2026.
- Phase 3 APPROACH study for HLP003 has surpassed 88% enrollment, on track for topline data readout in Q4 2026.
- Phase 2 data for HLP004 in GAD showed a 10-point improvement from baseline in HAM-A at 6 weeks (p<0.0001).
- Eric So returned as Interim CEO; several high-profile scientific appointments were announced.
- The White House Executive Order on psychedelic therapies was noted as a positive regulatory signal.
Financial Impact
Net loss widened by $66.4 million YoY to $148.0 million; operating cash burn nearly doubled to $133.3 million; cash position of $157.3 million plus $50 million post-period offering provides runway into late 2027 assuming current burn rate.
Risk Factors
- Phase 3 HLP003 trial failure or disappointing efficacy/safety data would be a severe negative catalyst.
- Cash burn rate of ~$133M/year implies current cash runway of ~18 months even after the $50M offering; further dilution likely.
- Regulatory and competitive landscape for psychedelic therapies remains uncertain despite White House executive order.
- Interim CEO structure and ongoing search for permanent CEO introduces management uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000048 |
| Document: cybininc-form6xk06x29x2026.htm | 0001833141-26-000048 |
| Document: 0001833141-26-000048-index-headers.html | 0001833141-26-000048 |
| Document: 0001833141-26-000048-index.html | 0001833141-26-000048 |
| Document: 0001833141-26-000048.txt | 0001833141-26-000048 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.36 (+2.47%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.36 (−4.56%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.36 (−3.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers